NASDAQ:AXSMAxsome Therapeutics Stock Price, Forecast & News

Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AXSM stock has increased by 2.9% and is now trading at $75.80. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Axsome Therapeutics.

Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Axsome Therapeutics.

Axsome Therapeutics Inc (NASDAQ:AXSM) issued its earnings results on Friday, May, 8th. The company reported ($0.88) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.28. View Axsome Therapeutics' earnings history.

9 analysts have issued 12-month target prices for Axsome Therapeutics' stock. Their forecasts range from $48.00 to $210.00. On average, they expect Axsome Therapeutics' stock price to reach $143.56 in the next year. This suggests a possible upside of 89.4% from the stock's current price. View analysts' price targets for Axsome Therapeutics.

Media headlines about AXSM stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Axsome Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAxsome Therapeutics.

Axsome Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 3,590,000 shares, a decrease of 14.9% from the April 30th total of 4,220,000 shares. Based on an average trading volume of 986,200 shares, the short-interest ratio is presently 3.6 days. Approximately 12.5% of the shares of the stock are sold short. View Axsome Therapeutics' Current Options Chain.

Some companies that are related to Axsome Therapeutics include Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Mylan (MYL), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Myokardia (MYOK), Emergent Biosolutions (EBS) and Reata Pharmaceuticals (RETA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), NVIDIA (NVDA), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Micron Technology (MU), Viking Therapeutics (VKTX), AbbVie (ABBV) and Advanced Micro Devices (AMD).

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.08%), RA Capital Management L.P. (5.14%), Alethea Capital Management LLC (2.67%), VR Adviser LLC (2.18%), State Street Corp (1.78%) and Invesco Ltd. (1.78%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View institutional ownership trends for Axsome Therapeutics.

AXSM stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Cormorant Asset Management LP, UBS Group AG, Janney Montgomery Scott LLC, Driehaus Capital Management LLC, Chartwell Investment Partners LLC, Blair William & Co. IL, and Baldwin Brothers Inc. MA. View insider buying and selling activity for Axsome Therapeutics.

AXSM stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., VR Adviser LLC, Pictet Asset Management Ltd., Fairmount Funds Management LLC, BlackRock Inc., Two Sigma Advisers LP, Nuveen Asset Management LLC, and Sofinnova Investments Inc.. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad, and Nick Pizzie. View insider buying and selling activity for Axsome Therapeutics.

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXSM stock can currently be purchased for approximately $75.80.

Axsome Therapeutics has a market capitalization of $2.81 billion. The company earns $-68,350,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.

The official website for Axsome Therapeutics is axsome.com.

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company can be reached via phone at 212-332-3241.